Replies to post #26863 on RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, OT - Just wondering what you think about Labopharm's once-daily formulation of the antidepressant Trazodone? It's up for approval on July 18th. Since Trazodone is already on the market, I figure this should be a relatively easy approval, going through the 505(b)(2) approval pathway.

Any idea how this might fare in the competitive antidepressant marketplace?

Thanks for any comments :o)